FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens

All NewsJune 18, 2026

FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT